TY  - GEN
AU  - Volker Schirrmacher
AU  - Philippe Fournier
TI  - Harnessing oncolytic virus-mediated immunity
SN  - 978-2-88919-450-6
PY  - 2015///
PB  - Frontiers Media SA
KW  - anti-tumor activity
KW  - immunovirotherapy
KW  - oncolytic virus
KW  - oncolytic virotherapy
KW  - tumor-associated antigen
KW  - immunotherapeutic approaches
KW  - anti-viral response
N1  - Open Access
N2  - Oncolytic viruses (OVs) have emerged as a promising anticancer treatment. OVs selectively infect, replicate in, and kill tumor cells. Oncolytic viral therapy occurs in two phases: an initial phase where the virus mediates direct oncolysis of tumor cells, and a second phase where an induced post-oncolytic immune response continues to mediate tumor destruction and retards progression of the disease. For a long time, the therapeutic efficacy was thought to depend mainly on the direct viral oncolysis based on their tumor selective replication and killing activities. But the post-oncolytic anti-tumor activity induced by the OV therapy is also a key factor for an efficient therapeutic activity. The topic adresses various strategies how to optimize OVs anti-tumor activity
UR  - http://journal.frontiersin.org/researchtopic/1613/harnessing-oncolytic-virus-mediated-antitumor-immunity
UR  - https://directory.doabooks.org/handle/20.500.12854/49124
ER  -